Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The study by the University of Oxford’s Department of Oncology and Kennedy Institute, supported by the NIHR Oxford Biomedical Research Centre (BRC), suggests that pancreatic cancer can be categorised in terms of a person's own immune system.

Peppette filing a sample tray

Researchers in Oxford have found that an individual’s immune system – and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.

The study by the University of Oxford’s Department of Oncology and Kennedy Institute, supported by the NIHR Oxford Biomedical Research Centre (BRC), suggests that pancreatic cancer can be categorised in terms of a person's own immune system. The research also involved colleagues from the universities of Cambridge, Birmingham, Leeds and Maastricht.

The paper, Immuno‐phenotypes of Pancreatic Ductal Adenocarcinoma: Meta‐analysis of transcriptional subtypes, is published in the International Journal of Cancer.

Pancreatic cancer is an aggressive cancer and has limited treatment options. In the early stages of the disease, the tumour often causes few symptoms, which can make it difficult to diagnose. After diagnosis, only 5% of patients survive for five years. Even after an operation in the earliest stages of the disease, only 20% of patients are alive after five years.

Read more (Department of Oncology website)

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.